The ARWR Paradox: Analysts Bullish But Forecast -3.92% Fall
July 25, 2019 at 09:50 AM EDT
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Arrowhead Pharmaceuticals Inc (ARWR). The average 12-month price target for ARWR — averaging the work of 6 analysts — reveals an average price target of $28.08/share..